In recent years, significant progress has been made in the study of molecular pathology of gliomas, and a series of molecular markers have been discovered that are helpful for clinical diagnosis, prognostic judgment, and treatment guidance, such as IDH1/2 gene mutation, chromosome 1p/19q co-deletion, and MGMT promoter methylation (5). This evidence concerns the gene IDH1 and central nervous system cancer.